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Ayurveda isthe ancient (before 2500BLC.) Indian sytem ofhealth care andlongvity. It involves a
holisticviewofman, his health, and illness. Ayurvedic treatment ofadisease consists ofsalubrious
use ofdrugs, diets, and certain practices. Medicinal preparations are invariablycomplex mixtures,
based mosdy on plant products. Around 1,250 plants are currently used in various Ayurvedic
preparations. Many Indian medicinal plants have come under scientdfic scrutiny since the middle
ofthe nineteenth century, although in a sporadic fashion. The first significant contibution from
Ayurvedic materiamedicacamewith theisolation ofthehypertesive alkaloidfromthesarpgd-
ha plant (Rauwo4Sasrpentina), valued in Ayurveda for the treatment ofhypertension, mnia,
and insanity. This was the first important ancient-modem concordance inAyurvedicplants. With
the gradual coming ofage of chemistry and biology, disciplines central to the study of biologic
activities ofnatural products, many Ayurvedic plants have been reinvestigated. Our work on
Commiphora wighti gum-resin, valued in Ayurveda for correcting lipid disorders, has been
described insomedetail; basedon theseinvestigations, amodemantihyperlipoproteinemicdrgis
on the market in Indiaand some other countries. There has also been concordance for a fewother
Ayurvedic crude drugs such asAsparagzu rcemosues Cedrw deodara, and Psoraeacoryhflk KIey
work. y-aminobutyric acid, antihyperlipoproteinemic drug, Asparagus racemosus, Ayurveda,
bakuchiol, Cedrus dkodara Commiphora wighsti GABA, guggulsterones, himachalol, Psora/ca
corylifolia, reserpine, Rauwo4fia serpentina. Environ Health Perspect 107:783-789 (1999).
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In the early development of modern medi-
cine, biologically active compounds from
higher plants have played a vital role in pro-
vidingmedicines to combatpain anddiseases.
For example, in The British Pharmacopoeia of
1932 (1), over 70% oforganic monographs
were on plant-derived products. However,
with the advent ofsynthetic medicinals, and
subsequently ofantibiotics, the role ofplant-
derived therapeutic agents significantly
dedined (mostly) in the economically devel-
oped nations. Thus, in the 1980 edition of
the The British Pharmacopoeia (2), the share
ofplant-based monographs fell to approxi-
mately 20%. In terms ofnew chemical enti-
ties introduced as medicinal agents over the
past several decades, the share ofplant-based
drugs has been no more than 2% (3).
However, plant-derived medicinals continue
to occupy an important niche in the treat-
ment of diseases worldwide. Thus, most of
the recently introduced plant-based drugs
have been innovative in character and repre-
sent outstanding contributions to therapeu-
tics. These drugs include several anticancer
agents such as podophyllotoxin, paclitaxel,
camptothecin, or compounds based on these
as lead structures; each of these classes of
compounds exhibit their anticancer activity
by distinct mechanisms (3). It has been esti-
mated that in the United States, 25% ofall
prescriptions dispensed from community
pharmacies during the period 1959-1980
contained plant extracts or active principles
derived therefrom (4). Even now, 75-80% of
theworld population depends on crude plant
drug preparations to treat their health prob-
lems, although this may be mostly because of
economicconsiderations.
In the last two decades, there has been a
new trend in the preparation and marketing
ofdrugs based on medicinal plants (3,5-8).
These preparations, labeled herbal drugs or
phytomedicines, are single plant extracts or
fractions thereof and are distinct from the
pure chemical entities of molecular drugs
(3). These new plant-derived products are
carefully standardized, and their efficacy and
safety for a specific application have been
demonstrated. The present global market for
these products has been estimated to be
approximately $20 billion U.S. and is grow-
ingat the rate of15-20% annually (3).
Thus, plant-based therapeutic agents con-
tinue to have scientific, social, and commer-
cial significance and appear to be gathering a
momentum in health-relevant areas.
A study ofthe process by which the tra-
ditional or more recent plant-based molecu-
lar drugs or the new breed of herbal drugs
came to be used in present-day medicine
reveals that, in over 70% of the cases, the
starting point has been some reference to the
use of that plant as an indigenous cure in a
folklore or traditional system ofmedicine of
one culture or another. Some examples are
codeine, ephedrine, quinine, and emetine
among the traditional molecular drugs;
reserpine, artemisinin, and podophyllotoxin
(lead structure) from the period after the tra-
ditional molecular drug era; and garlic, gin-
seng and St. John's wort of the currently
popular herbal drugs. Thus, this paper high-
lights the modern drug discovery potential
ofthe plants described in various traditional
systems ofmedicine or in the folklore ofvar-
ious countries, which has been previously
emphasized (3,9-12). It is with this back-
ground that I would like to discuss the
potential of and opportunity in Ayurvedic
materia medica. However, it seems appropri-
ate to brieflydescribeAyurveda for those not
familiarwith this Indian heritage.
Ayurveda
The origin ofAyurveda has been lost in pre-
historic antiquity, but its characteristic con-
cepts appear to have matured between 2500
and 500 B.C. in India. The word "Ayurveda"
is derived from "ayus (r)," meaning life, and
"veda," meaning knowledge; thus, Ayurveda
literally means "science of life." It is the
ancient Indian system of health care and
longevity. Ayurveda takes a holistic view of
man, his health, and illness. It aims at posi-
tive health, which has been defined as awell-
balanced metabolism coupled with a healthy
state of being. Disease, according to
Ayurveda, can arise from the body and/or
the mind because of external factors or
intrinsic causes. Ayurvedic treatment is
aimed at the patient as an organic whole,
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and treatment consists of salubrious use of
drugs, diets, and certain practices (13).
Ayurveda has a vast literature in Sanskrit
and various Indian languages, covering vari-
ous aspects ofdiseases, therapeutics, andphar-
macy. It has evolved its own theoretical base,
which is difficult to comprehend in terms of
modern scientific concepts, at least at present.
However, here we are concerned only with
theexplorationofits materiamedica.
Pharmaceutics occupies an important
place inAyurveda. Medicinal preparations are
complex mixtures including plant- and ani-
mal-derived products, minerals, and metals.
Plants form a dominant part ofAyurvedic
pharmacopoeia. The earliest references to
such plants are found in the Rig Vedaand the
Atharva Veda, dating back to the second mil-
lennium B.C. The Charaka Samhita (- 900
B.C.) (14,15) is the first recorded treatise filly
devoted to the concepts and practice of
Ayurveda; its primary focus was therapeutics.
This work listed 341 plants and plant prod-
ucts for use in medicine. The next landmark
in Ayurvedic literature was the Sushruta
Samhita (- 600 B.C.) (16,17), which has spe-
cial emphasis on surgery. It described 395
medicinal plants, 57 drugs ofanimal origin,
and 64 minerals and metals as therapeutic
agents. Sushruta, the father ofsurgery, lived
and practiced surgery in Varanasi, India,
approximately 2,500 years ago. Another
important authority in Ayurveda was
Vagbhatta ofSind, in present day Pakistan,
who practiced around the seventh century
A.D. His workAshtangaHridayais considered
unrivaled for the principles and practice of
medicine (13,18). The Madhava Nidana
(- 800-900 A.D.) was the next important
milestone; it is the most famous Ayurvedic
work on the diagnosis ofdiseases (16). The
last celebrated writer on Hindu medicine was
Bhava Mishra of Magadha, whose treatise
BhavaPrakasha, written around 1550, is held
in high esteem by modern Ayurvedic practi-
tioners for its descriptions ofapproximately
Table 1. Classification of plant drugs according to
Charaka Samahita(21).a
No. Sanskrit name Use
1 Jivaniya Promoting longevity
3 Lekhaniya Antiobesity
6 Dipaniya Promotor of digestion
7 Balya Promoting strength
8 Varnya Promoting complexion
15 Krmighna Anthelmintic
17 Stanyajanana Galactagogue
23 Vamanopaga Emetic
24 Virechanopaga Purgative
35 Mutravirechaniya Diuretic
36 Kasahara Antitussive
38 Svayathuhara Antiinflammatory
39 Jvarahara Febrifuge
47 Vedanasthapana Analgesic
50 Vayahsthapana Antiaging
470 medicinal plants (19). Other than these
monumental treatises, many (> 70) Nighantu
Granthas (pharmacy lexicons) were written,
mostly between the seventh and sixteenth
centuries (13,16). Raj Nighantu by Narhari
Pandita and Madanpala Nighantu by
Madanpala are considered masterpieces on
medicinalplants (12.
All ancient texts on Ayurveda divide
medical knowledge into eight branches
(Ashtanga), and this is no different from the
contemporary approach. Also, Ayurvedic
descriptions of diseases are much like the
modern delineation (20). Plant-derived
drugs have been categorized according to
their pharmacologic/therapeutic action. For
example, in the Charaka Samhita, drugs
were classified into 50 groups (Table 1) (21).
Ayurveda, in its prime, was a cogent, sci-
entifically organized discipline. Ayurvedic
texts were much respected in neighboring
countries, as evidenced from their translation
into Greek (300 B.C.), Tibetan and Chinese
(300 A.D.), Persian and Arabic (700 A.D.),
and several languages of other Asian people
(22,23). Currently, Ayurveda is widely prac-
ticed in the Hindustan peninsula (India and
the neighboring countries) and, in recent
years, has attracted much attention in eco-
nomically developed countries such as those
in Europe and in the United States and
Japan (24).
Ayurvedic Drugs
There are approximately 1,250 Indian medic-
inal plants (25) that are used in formulating
therapeutic preparations according to
Ayurvedic or other traditions. Several ofthese
plants came under the contemporary (mod-
ern) scientific scrutiny since the middle ofthe
nineteenth century. A fairly comprehensive
account ofearly research covering the period
up to the early 1930s was incorporated into
book form (26), and this book was revised
and updated in 1958 (27). In 1961, the
Central Council ofAyurvedic Research,
Government ofIndia, arranged a conference
ofreputed Ayurvedic physicians to prepare a
list ofthe most usefulAyurvedicplants. Thus,
a list of 190 single plantdrugs emerged. This
wasfollowed-up bythe formulation ofa com-
posite drug research scheme by the Ministry
of Health, in collaboration with the Indian
Council ofMedical Research and the Council
ofScientific and Industrial Research. The aim
ofthis scheme was to indude prominent sci-
entists of the country involved in both
Ayurvedic and modern dinical practice, phar-
macology, pharmacognosy, and chemistry in
an effort to evaluate the classical claims in
terms of contemporary scientific knowledge.
Results ofthese investigations have been sum-
marized(28,29).
Two other major screening programs
were launched around 1964, one at the
Central Drug Research Institute (CDRI),
Lucknow, India (30), and the other at Ciba-
Geigy Research Centre, Mumbai, India (31).
Both of these programs covered the Indian
flora in general, without reference to any use
ofthese plants in Ayurveda or in any Indian
folklore. The outcome oftheCiba-Geigy pro-
gram has not been madepublic. On theother
hand, the CDRI effort, spanning a period of
20 years, covered over 2,500 plants that were
screened for a variety ofbiologic activities.
Interesting leads were apparently obtained,
andthese results havebeensummarized (32).
Indian medicinal plants have been stud-
ied in various universities and research insti-
tutes; this work is still in progress, with
results beingreported inprofessionaljournals.
Table 2. Some Ayurvedic crude drugs that have received pharmacologic and clinical support for their
therapeutic claims.
Plant Active Type of activity
Botanical name Sanskrit name component (references)
Acoruscalamus Vacha Unknown Tranquilizer(28)
Adhatodazeylanica Vasa Vasicine Bronchodilator, oxytocic(35)
Aloe vera Kumaari Unknown Antiinflammatory(36-35)
Andrographispaniculata Bhuinimba Andrographolide Hepatoprotector (39,40)
Asparagusracemosus Shatavari Shatavarn-1 Antiabortifacient (41-43)
Azadirachta indica Nimb Gedunin Antimalarial (44,45)
Bacopamonneri Brahmi Baccosides Improves memory(46)
Boerhaavia diffusa Punarnava Unknown Diuretic, antiinflammatory (28)
Boswelliaserrata Sallakee Boswellic acids Antiarthritic(47,48)
Butea frondosa Palasha Palasonin Anthelmintic(28,49)
Cedrusdeodara Devadaru Himachalols Spasmolytic(50,51)
Centellaasiatica Mandookpaarni Asiaticosides Skin diseases, psychotropic (28,52)
Commiphora wightti Guggulu Gugguisterones Hypolipidemic(53-55)
Curcuma longa Haridra Curcumin Antiinflammatory (48,56)
Holarrhena antidysenterica Kutaja Conessine Antidysenteric (29)
Phyllanthusniruri Bhoomyaamalakee Unknown Hepatoprotector(57,55)
Picrorrhizakurroa Katukaa Picroside, kutcoside Hepatoprotector (59-62)
Psoralea corylifolia Bakuchi Psoralen, bakuchiol Antileucoderma, antibacterial(25)
Rauwolfia serpentina Sarpagandha Reserpine Tranquilizer(63,64)
Swertia chirata Kairata Unknown Hepatoprotector (65,66)
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Two publications (33,34) have attempted to
cover these findings.
In a significant number ofcases, current
data from these and other studies corroborate
the main claims of these plants according to
traditional use. Some examples are shown in
Table 2 (35-66). This concordance is mean-
ingftl; to emphasize its scientific, commercial,
and social potential, I would like to elaborate
on someoftheseexamples.
Psoralea corylifolia (bakuchi). This is an
erect annual found almost throughout India.
Its seed powder is valued inAyurveda for the
treatmentofvitiligo, psoriasis, and inflamma-
tory diseases of the skin (67). Chemical and
pharmacologic investigations (29,68,69) led
to the isolation of the active principle, pso-
ralen (Figure 1), in the mid-1930s; psoralen
has been shown to stimulate the formation of
melanin (70). Psoralen is used therapeutically
for the treatment ofleucoderma. More recent
investigations have led to the isolation ofthe
meroterpene bakuchiol (Figure 1) (71-73)
and other related compounds (74).
Bakuchiol has been shown to posses potent
antibacterial activity (29) and is useful for the
treatment of psoriasis (75). Recently, baku-
chiol has been shown to be a DNA poly-
merase inhibibitor (76).
Rauwolfia serpentina (sarpagandha).
This is a famous Ayurvedic plant because it
represents the earliest (- 1950) contribution
ofAyurveda to modern drug development.
Rauwolfia serpentina received international
attention and rekindled the interest of
researchers in exploring higher plants for
innovative leads. Roots ofthis plant are val-
ued in Ayurveda for the treatment ofhyper-
tension, insomnia, and insanity (63); in
Hindi speaking areas, this plant is called
"pagle ki booti" (plant for the insane).
Significant pharmacologic, clinical, and
chemical work on the plant carried out in
India attracted the attention of the CIBA
Figure 1. Diagrams ofvarious chemical compounds present in some usefulAyurvedic plants.
group (Basel, Switzerland), who finally suc-
ceeded (in 1952) in isolating the sedative
principle, reserpine, a minor alkaloidal con-
stituent. Reserpine was introduced in the
market in 1953 and was heralded as a revolu-
tionary event in the treatment of hyperten-
sion, as it had the twin effect of lowering
high blood pressure and acting as a tranquil-
lizer (64).
Asparagus racemosus (shatavari). Roots
of Asparagus racemosus are reputed in
Ayurveda as galactagogue, and preparations
based on this drug (e.g., Shatavari sidh ghrit)
are often recommended in cases ofthreatened
abortion (28,7X). This plant contains several
glycosides, and one of these, shatavaran-I
(Figure 1) (41,42, has been shown to block
oxytocin-induced contractions in rat, guinea
pig, and rabbit uteri in vivo and in situ (78).
Galactagogue activity has also received some
experimental support (43).
Cedrus deodara (devadaru). Wood ofthe
Himalayan cedar has several medicinal attrib-
utes, and preparations based on this plant are
used to treat cough, bronchitis, and skin dis-
eases, among others (79). An oil obtained
from the wood is used in villages for treating
insect infestations on animals; there is suffi-
cient experimental support for this (80). The
essential oil ofthe wood has been thoroughly
examined chemically (81-83). Himachalol
(Figure 1), one of the constituents of the
essential oil, has been shown to possess potent
spasmolytic activity (50,51). Activity-guided
fractionation led to the identification of
himachalenes (Figure 1) as the antimange
compounds. A commercial preparation
(Flematic) based on this finding is being mar-
keted (84) in India as a broad spectrum agent
against various types of ectoparasites that
commonlyaffect animals.
Commiphora wightti (guggulu).
Commiphora wightti is another significant
contribution ofAyurveda to modern medi-
cine. Commiphora wightti is a small tree
belonging to the family Burseraceae; when
injured, the plant exudes a yellowish gum
resin that soon solidifies to an agglomerate of
tears or stalactitic pieces with balsamic odor.
This gum resin ("guggulu" in Sanskrit) is
renowned in Ayurveda for the treatment of
inflammatory disorders, rheumatoid arthritis,
lipid disorders, obesity, skin diseases, and
other ailments (85). Some of these claims
appeared to be supported by the results of
pharmacologic screening (53,86-89) carried
out during 1960-1969 on the crude drug. In
Sushruta Samhita, the description ofmedoro-
ga (obesity and associated lipid disorders) is
quite reminiscent of the modern concepts of
pathogenesis of atherosclerosis (Figure 2)
(90), and guggulu was recommended for
treatment. In 1969, few drugs with useful
hypolipidemic activity were on the market.
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Bioassay-guided separation eventually led, in
1971, to the isolation and characterisation of
two antihyperlipoproteinemic compounds, Z-
guggulsterone and E-guggulsterone (Figure 1)
(54,55). Both compounds have similar activi-
ty comparable (Table 3) to that ofclofibrate
(Figure 1), a synthetic hypolipemic drug that
became available on the marketin 1967.
Guggulu gum resin essentially consists of
an ethyl acetate-soluble fraction ( 45%) and
an insoluble carbohydrate gum (- 55%). The
latter is toxic to rats and is devoid of any
hypolipemic activity. The desired biologic
activity lies entirely in the ethyl acetate-soluble
fraction. This fraction has been extensively
chemically examined (54, 91-9) and consists
ofditerpenoids, triterpenoids, steroids, lig-
nans, fatty tetrol esters, etc. A review of this
work has been published (98). Approximately
4% ofthe active guggulsterones are present in
this fraction. Howeveracomparison (Table 3)
ofthe activityofthis fractionwith thatofpure
guggulsterones showed a vastly disproportion-
ate activityforthe total extract, possiblydue to
synergistic or additive activity ofsome ofthe
components of the mixture (12). In view of
this, further development ofthe product (col-
lectingpharmacologic, biochemical, toxicolog-
ic, teratogenic, mutagenic, and dinical data)
was carried out on astandardized ethyl acetate
extract, code-named gugulipid, containing at
least 4% guggulsterones. Gugulipid exhibits a
dose-dependent lowering ofserum cholesterol
and triglycerides in normal and hyperlipidem-
ic rats, rabbits, and monkeys. A study ofthe
lipoprotein profile in rabbits (Table4) showed
Ancient Modern
1
'I,
Manycomplications Manycomplications
Figure 2. Analogy drawn between the modern
concept of pathogenesis of atherosclerosis and
the ancientconceptofthe pathogenesis ofobesity
and associated lipid disorders. Definitions: shlesh-
malahara, rich food (fats, proteins); vata vikaras,
diseases ofthe nervous system.
a significant enhancement in the level ofthe
desired high-density lipoproteins and reduc-
tion in the unwanted low-density lipids (99).
Gugulipid also caused regression ofatheroma-
tous lesions induced in rabbits by a fat-rich
diet. Gugulipid has a multifocal action: it
inhibits cholesterol biosynthesis, mobilizes fat
from tissues, and increases secretion ofbile
acids (100-IOZ). Although gugguisterones are
pregnane derivatives, they are completely
devoid of any estrogenic, antiestrogenic, or
progestational activity. Gugulipid was deared
for registration in India in 1986, and thedrug
has been manufactured and marketed in India
since 1987. Gugulipid isnowbeingsold inthe
international market.
Thediscoveryofantihyperlipoproteinemic
guggulsterones in the guggulu resin was an
event ofconsiderable interest because these
compounds represent a new structural type in
hypolipidaemic agents (103). Consequently, a
number ofpregnane derivatives were synthe-
sized and evaluated for their hypolipemic
activity. One ofthese (code no. 81/574) was
found to be at least as active asguggulsterones
and iscurrentlyundergoingclinicaltrials(99).
Additional Concordance
In recentyears wehavestudiedseveral groups
ofAyurvedic plants bymodern in vitrometh-
ods, in coiloboration with various groups. A
briefaccount ofthese investigations follows.
Table 3. A comparison of cholesterol-lowering activity of guggulsterones, clofibrate, and some guggulu
fractions in rats.
Product Percentlowering of serum lipids Percent inhibition of
(100 mg/kg, Normal rats Ratsfed highfat cholesterol biosynthesis
oral for30 days) Cholesterol Triglycerides Cholesterol Triglycerides in ratliverhomogenate
Ethyl acetate soluble 34 24 46 24 30
(gugulipid)
Guggulsteronesa 35 28 48 29 35
Total ketonesb 30 26 29 20 22
Nonketonicb 15 16 25 15 10
Clofibrate 43 30 - - 40
Data from Nand (991.
'Mixture ofZ- and E-guggulsterone isomers (80:20).1'These represent ketonic and nonketonic fractions ofthe neutral cut
ofthetotal ethyl acetate-soluble portion ofthe gum resin (15).
Table 4. Lipid-lowering activity of gugulipid
Percent change in serum lipoproteins
Testsystem LDL VLDL HDL
Hyperlipemic rabbits 50mg/kg P.0./90 days -25 -27 +29
Normal monkeys 60mg/kgP.0/90days -50 -30 -
Abbreviations: HDL, high density lipoprotein; LDL, low density lipoprotein; VLDL, very low density lipoprotein.
Data from Nand(99).
Table 5. Modern scientific evaluation ofsomeAyurvedic memory-enhancing and antiaging plants.
Plant Enzyme inhibition (%) Receptor binding (%)
(Sanskrit name) ACE AChE NMDA GABA(A/B) NGF
Acoruscalamus - - - - -
(vaccha)
Benincasahispida - - - - -
(kooshmand)
Celastruspaniculatus NI NI -
(jyotishmati)
Centellaasiatica - - - 82 (B)
(mandookpaarni)
Convolvulusmicrophyllus - - 55 - High
(shankhapushpi)
Nardostachysjatamansi - 90 -
(jataamansi)
Ocimumgratissimum 68 - NI
(tulsi)
Pluchea lanceolata 60 - - 99(B) 50
(raasna)
Terminalia chebula 82 - 53 53 (B) -
(haritaki)
Withaniasomnifera NI NI - >80(A,B)
(ashwagandha)
Abbreviations: AChE, acetylcholine esterase; ACE, angiotensin-converting enzyme; GABA(AB), y-aminobutyric acid; NGF,
nerve growth factor; NI, notinvestigated; NMDA, N-methyl-D-aspartic acid. The appropriate plantpart, as recommended
in Ayurveda, was extracted with methanol by room temperature percolation. For biological screening, the methanol-free
extract wastaken up in aqueous DMSO to get5 pg ofthe material/mL.
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Learning, memory, and cognitive disor-
ders. This area of research was selected for
three reasons: a) there is a paucity ofmodern
drugs/agents facilitating acquisition, reten-
tion, and retrieval ofinformation and knowl-
edge; b) with the increasing number ofelder-
ly people in the world population, the need
for drugs to treat cognitive disorders, such as
senile dementia and Alzheimer disease, have
acquired special urgency; and c) Ayurveda
claims that several plants, the so-called "med-
hya" plants, possess such activities.
The past two decades have seen tremen-
dous advances in the area ofbrain physiology,
learning, memory, and various brain disor-
ders, and a host ofmechanisms at molecular
level have been delineated (104-106).
Synapses-the junctions ofnerve cells repre-
senting the basic interactive unit ofneuronal
circuits-constitute the fundamental sys-
temic relationship within the brain.
Understanding how this interactive multi-
tude of neuronal circuitry is established ini-
tially, and refined continuously throughout
life, is fundamental to understanding the
molecular basis of learning and memory. At
present, an impressive array ofchemical enti-
ties affecting synapse formation, neuronal
differentiation, neurotransmission, nerve
growth and repair, and several other func-
tions are recognized. Approximately 50 neu-
rotransmitters belonging to diverse chemical
groups have been identified in the brain
(107). Receptors, which are activated by
these chemicals, assume special importance in
the present context. Specifically, N-methyl-
D-aspartic acid (NMDA) andy-aminobutyric
acid (GABA) receptors have been implicated
in learning and memory (108-111). It has
been further postulated that GABAB antago-
nists may enhance memory (108), whereas
the NMDA receptor has the ability to medi-
ate synaptic plasticity (111). Acetylcholine,
the first neurotransmitter to be characterized,
has a very significant presence in the brain;
recently, Winkler et al. (112) determined
that acetylcholine is essential forlearning and
memory. Acetylcholine has been aspecial tar-
get for investigations for almost two decades
because its deficit, among other factors, has
been held responsible for senile dementia and
other degenerative cognitive disorders,
including Alzheimer disease (113-116).
Approximately 5% of the neurons in the
Table 6. Cholecystokinin (peripheral) receptor
binding assay oftriphala components
Plant Percent inhibition
Terminalia chebula 96
Terminalia bellerica 91
Emblicaofficinalis 76
The dried kernel-free fruits were extracted with methanol
hippocampus (the part ofthe brain central to
learning, memory, and emotions) disappears
with each decade after 50 years of age, and
the brain tries to compensate for this by fur-
ther growth ofthe neurites (neuron axon and
dendrites) (117), which are vital for normal
functioning ofthe brain. Thus, nerve growth
factor has an important role to play. Several
reports have suggested that angiotensin-con-
verting enzyme inhibitors (e.g., captopril)
may indirectly lead to improved cognitive
performance (116). There are several other
factors [e.g., gonadal steroid receptors
(118,119], that have a bearing on learning
and memory, but they are not relevant to the
currentwork.
The knowledge about neurotransmitters,
enzymes, growth factors relevant to memory
and learning, and cognitive disorders is
already being used for the discovery and
development of suitable therapeutic agents
(120,121). Major emphasis has been on
acetylcholine. Because the number of acetyl-
choline receptors dedines with advancing age,
inhibitors ofacetylcholine esterase (AChE),
which terminates the action ofacetylcholine,
have beenspecial targets fordevelopment.
We studied some oftheAyurvedic plants
reputed to be memory enhancers (medhya)
and antiaging drugs (Vayahsthapana) by
standard receptor binding and enzyme inhi-
bition techniques (Table 5), with the specific
aim of identifying any leads based on the
above considerations. It was gratifying to see
several positive results. Shankhapushpi (leaf
is one of the prime medhya plants of
Ayurveda; it may be useful for neural regen-
eration and synaptic plasticity. Jataamansi
(rhizome) appears to be an excellent candi-
date for a potential inhibitor of AChE.
Haritaki (fruit) is highly prized in Ayurveda
for antiaging; its extract has displayed several
activities. Ashwagandha (root) is another
important antiaging plant. We have investi-
gated this plant in some detail because its
extract showed high affinity for both GABAA
and GABAB receptors. Receptor-binding
assay-guided fractionation of the crude
methanol extract resulted in a butanol frac-
tion with retention ofGABAB receptor activ-
ity [concentration that inhibits 50% (IC50)
-
47 pg/mL] and an aqueous fraction that
retained both GABAA (IC50 - 0.37 pg/mL)
and GABAB (IC50
- 15.8 pg/mL) affinities.
Gastrointestinal disorders, satiety and
feeding behavior. Cholecystokinin (CCK) is
a polypeptide hormone, widelydistributed in
the gastrointestinal tract and nervous system
(both peripheral and central); it plays a major
role in the digestive process. CCK also occurs
in the brain, where it acts as a neurotransmit-
ter and neuromodulator. CCK exists as sever-
al different molecular species: CCK-58,
CCK-39, CCK-33, CCK-8, and CCK-4.
The octapeptide CCK-8, for example, pre-
dominates in the brain. Also, there are at least
two types ofCCK receptors (122-124).
Over the past 10-15 years, there has
been much activity in the development of
potent and selective CCK agonists and
antagonists because these agents may lead to
novel therapy for the treatment ofdisorders
such as gastrointestinal disturbances, pancre-
atitis, gastric and pancreatic carcinomas,
obesity, and cognition dysfunction, in which
CCK has been implicated. Several such mol-
ecules are under active development (124).
There are also satiety agents, fashioned after
CCK, which may fight obesity (125).
It seemed worthwhile to evaluate the
three components ofTriphala (three fruits),
an Ayurvedic remedy for treating various gas-
trointestinal disorders. The three fruits are
products of Terminalia chebula (Sanskrit: har-
itaki), Terminalia bellerica (bibhitaka), and
Emblica officinalis(aamalaki); haritaki has also
been recommended in Ayurveda for treat-
ment of obesity. The methanol-extracted
material from the three fruits was evaluated in
vitro by radioligand binding assays (Table 6)
(126). As is evident from these data, the three
extracts showed good affinity for the CCK
receptor, thus, offering good opportunity for
the isolation and evaluation of new and possi-
bly clinically useful ligands. My laboratory
investigated the extract from T bellerica in
some detail and isolated several pure com-
pounds, one ofwhich (code name B3EA-10;
melting point 190-192°C) showed high
affinity (IC50 - 1.8 pg/ mL).
Hairgrowthpromotingactivity. A num-
ber ofplants have been recommended in the
Ayurvedic system for promoting the growth
ofhead hair, as distinct from the treatment of
alopecia, male pattern baldness. Because the
research division of Hindustan Lever
(Mumbai, India) had devised a system for
screening plant extracts that may promote
Table 7. Angiogenesis assay(chorioallantoic membrane assay).
Botanical Sanskrit Plant part Results
Embellica officinalis Amalaki Fruit
Hedychium spicatum Shati Root Newgrowth
Hemidesmus indicus Saariva Root Bundling and newgrowth
Nardostachysjatamaansi Jataamaansi Root Newgrowth
Nigella sativa Krishna jeeraka Seed
Saussurea lappa Kushth Root Bundling and newgrowth
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by room temperature percolation. For biological screen-
ing, the methanol-free extract was taken up in aqueous
DMSO to get 5 pg ofthe material/mL.
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hair growth, I sent them extracts of plants
selected on the basis ofclaims ofhair growth
in the traditional medicine literature. The
test system is based on the premise that trans-
port ofnourishment to the hair root, the site
of biochemical activity, would be facilitated
by strengthening the hair root system. For
this they used the chicken chorioallantoic
membrane assay, a model for angiogenesis
(neovascularization). Normally, angiogenesis
is unimportant except during growth and
wound healing, and researchers have been
seeking inhibitors ofangiogenesis in search of
anticancer compounds (127). However, my
interest was to see if any of the traditional
plants promote neovascularization because
thiswouldaid bloodsupplyto thehairpapilla.
Table 7 summarizes these investigations; sev-
eral positive results are evident.
Conclusion
The materia medica ofAyurveda, and other
similar repositories ofknowledge from other
cultures, represent a valuable resource for
development of not only medicinal prepara-
tions but also nutraceuticals and cosmaceuti-
cals according to modern-day requirements.
However, these claims must be critically eval-
uated in terms of modern scientific parame-
ters. When such a project is envisaged, some
prerequisites must be met. It is important to
carefully correlate the disease description in
the ancient literature with the modern etiolo-
gy and clinical picture to ensure correct cor-
respondence. In the Ayurvedic literature,
there was much stress on the collection of
plant material during a particular season,
from a particular locale, and at a certain time
of day. It is now well established that the
concentration and profile of secondary
metabolites in a plant depend on environ-
mental, nutritional, and and photoperiodici-
ty factors. Thus, the correct type of plant
material is essential. Because traditional plant
preparations have significant historical back-
ground, it may be ethical to clinically evalu-
ate these first and then collect modern toxi-
cologic data. For herbal preparations, it may
not be essential to pinpoint the active princi-
ple(s), but it is desirable to have this informa-
tion. In any case, important classes of com-
pounds essential for biologic activity must be
delineated. All of this knowledge will be
essential for proper standardization ofa prod-
uct. If a product is too complex, it must be
standardized in terms of biologic activity
parameters. This will require much research
effort.
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